EMA Authorised: Tuzulby (methylphenidate hydrochloride) — Neuraxpharm Pharmaceuticals S.L.

View source ↗

Summary

A new methylphenidate hydrochloride product, Tuzulby, has been authorised in the EU for Attention Deficit Disorder with Hyperactivity (ADHD) by Neuraxpharm Phar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Disorder with Hyperactivity

Drugs mentioned

• Tuzulby (methylphenidate hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Attention Deficit Disorder with Hyperactivity. MAH: Neuraxpharm Pharmaceuticals S.L.. Decision date: 12/08/2026